Tamsulosin Transdermal Patch Using Composite Adhesive Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The poor solubility of tamsulosin in conventional transdermal adhesives and skin irritation issues hinder the development of effective transdermal patches for its delivery, as tamsulosin is poorly soluble in both aqueous and organic solvents, and existing permeation enhancers can cause skin irritation.
Innovation Solution
A composition for transdermal patches comprising tamsulosin or its pharmaceutically acceptable salt, polyisobutylene adhesive, an aprotic solvent like dimethylsulfoxide, an unsaturated fatty acid or alpha-hydroxy acid, a lipophilic permeation enhancer, and a matrix modifier, which facilitates solubilization and reduces skin irritation by appropriate proportions of solvents and co-solubilizers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If conventional transdermal adhesives are used for tamsulosin delivery, then the patch structure is simple, but tamsulosin solubility is poor
Solution Approach 1:
The patent uses a composite adhesive system combining polyisobutylene with specific solvents (dimethylsulfoxide, dimethylformamide, dimethylacetamide) and co-solubilizers (unsaturated fatty acids like oleic acid, alpha-hydroxy acids like lactic acid) to create a matrix that simultaneously provides adhesive properties and enhanced tamsulosin solubility. This composite approach allows the patch to maintain structural simplicity while achieving adequate drug solubility through synergistic material combinations.
2Productivity
If permeation enhancers are added to improve tamsulosin delivery, then transdermal flux is enhanced, but skin irritation increases
Solution Approach 1:
The patent modifies the chemical parameters of the adhesive matrix by incorporating specific solvents and co-solubilizers that change the solubility and permeability characteristics of the system. The use of dimethylsulfoxide combined with unsaturated fatty acids creates a microenvironment that enhances tamsulosin permeation through the skin without requiring traditional permeation enhancers that cause irritation. This parameter change in the adhesive composition achieves improved flux while maintaining skin compatibility.
3Ease of operation
If oral formulation is used for tamsulosin, then administration is simple, but peak concentrations cause side effects
Solution Approach 1:
The transdermal patch provides continuous delivery of tamsulosin through the skin, maintaining steady therapeutic concentrations without the sharp peaks associated with oral administration. The adhesive matrix continuously releases the drug over extended periods (at least 168 hours), ensuring uninterrupted therapeutic action while avoiding the sudden high concentrations that cause postural hypotension and other side effects.
4Duration of action of moving object
If transdermal patch is designed for extended duration, then duration of action is prolonged, but drug solubility in adhesive matrix becomes limiting
Solution Approach 1:
The patent introduces solvents (dimethylsulfoxide, dimethylformamide, dimethylacetamide) and co-solubilizers (unsaturated fatty acids, alpha-hydroxy acids) as intermediary substances that facilitate tamsulosin dissolution in the polyisobutylene adhesive matrix. These intermediaries act as mediators between the poorly soluble tamsulosin and the hydrophobic adhesive, enabling adequate drug loading and sustained release over extended periods of at least 168 hours.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution enables the stable and prolonged transdermal delivery of tamsulosin with reduced skin irritation, achieving significant flux and extended duration of action, with patches designed for replacement once a week, maintaining effective drug delivery for at least 168 hours.
Implementation Method 1
an aprotic solvent in which tamsulosin dissolves readily
Implementation Method 2
a lipophilic permeation enhancer
Implementation Method 3
an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids
Data Source
AI summary
In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.